Douglas Falk

Douglas Falk is the Chief Executive Officer & Co-Founder at Vita Therapeutics. Prior to this, they were a Principal - Equity Research Analyst at Brown Advisory from September 2015 to October 2019. Douglas Falk's focus has been on Biotechnology and Healthcare. Before Brown Advisory, Merrill Lynch employed Douglas Falk as an Investment Analyst from January 2014 to December 2015. And prior to Merrill Lynch, Falk interned as an M&A Research Analyst at Lazard from September 2012 to December 2012.

Douglas Falk has a Master's degree in Biotechnology from The Johns Hopkins University and an Economics and Business Management degree with a concentration in Finance from Goucher College.

Amy Wesa - SVP of Translational Research, Peter Andersen - Co-Founder, and Steven S. Brooks - SVP, Medical Sciences & Regulatory Affairs report to Douglas Falk.